Biotechnology

Enquiry IconContact Us

The biotech industry includes bio-pharma, bio-services, bio-agri, bio-industrials and bioinformatics. Biopharma is a rapidly growing segment that accounts for a dominant share in this sector. Advancements in biotechnology have enabled researchers to evaluate and identify target biomarkers/cell receptors to develop targeted and personalized therapies. Scientific research and technological advancements have resulted in the emergence of various personalized medicines that are undergoing research. According to research conducted by the Personalized Medicine Coalition, 42% of all compounds and 73% of oncology compounds in the pipeline possess the potential to be personalized medicine. Moreover, according to this study, it is expected that companies will increase their investment in R&D of personalized medicines by 1/3rd over the following five years. The study found that over 20% of drugs approved in 2014 were personalized medicines.

The biotechnology sector has witnessed some disruptive innovations such as gene and cell therapies, immunotherapy, and antibody drug conjugates. Advancement in stem cell therapy is resulting in effective treatment therapies for chronic conditions, organ growth and repair and disease prevention.

Key Challenges

Biotech products have extensive application in oncology and autoimmune disease treatment. However, the cost of these drugs is high owing to extensive research and trials that need to be carried out for the same. Therefore, there is constant pressure to reduce price and increase accessibility, especially in emerging economies. In the U.S., companies are facing reimbursement issues with respect to biopharmaceutical products. Besides, there are regulatory and scientific challenges faced by the sector. Scientific research for new molecules and targeted therapies is capital intensive and challenging owing to growing concern for safety of the drug.

Also, there is lack of awareness about personalized medicine among most healthcare providers, which may hamper its adoption. Clinical adoption of biotechnology products is essential for its success. However, it significant scientific evidence and backing is required to ensure its safety.

“Translating genomic discoveries into personalized medicines entails overcoming substantial scientific, regulatory, and economic challenges, including identifying validated biomarkers, as well as developing personalized therapeutics and clinically relevant diagnostic tests.”

  • Tufts Center for the Study of Drug Development

Opportunities

The biopharmaceutical sector offers vast lucrative growth opportunities. High efficacy and safety of biopharmaceutical products has led to a growth in their demand, Furthermore, consumers are willing to pay high prices for biopharmaceutical products compared to other conventional products. Biopharmaceutical brands have set new standards for blockbuster drugs by recording an annual average sale of over US$ 2bn. Drugs such as Humira have generated sales revenue of over US$ 10bn.

Governments in emerging economies are endorsing biosimilars as cost-effective alternatives to biotech products, which is expected to create significant growth opportunities for manufacturers of generic drugs. Therefore, cost-effectiveness and high quality are prime parameters that need to be considered while developing biosimilars. Recent and upcoming biologic patent expirations include the following:

  • Erbitux (cetuximab) - February 2016
  • Rituxan (rituximab) - September 2016
  • Herceptin (trastuzumab) - June 2019
  • Avastin (bevacizumab) - July 2019
  • Aranesp (darbepoetin alfa) - May 2024
  • Enbrel (etanercept) - November 2028

Companies such as Teva Pharmaceuticals, Hospira, Sandoz, and Amgen are focusing on development of biosimilars and vaccines as preventive measures in addition to treatment. For instance, in 2015, Zarxio TM became the first biosimilar to be approved in the U.S. market. The EMA approved Mosquirix, a malaria vaccine, in the same year. Extensive research is currently underway to develop a dengue vaccine, which could be another breakthrough pharmaceutical product in the near future.

Conclusion

The increasing research in the biotechnology sector is expected to result in higher number of biopharmaceutical products seeking FDA approvals. Biopharmaceuticals are positioned to be promising treatment solutions that would improve patient outcomes and help with reduction of the cost of drug development.

View More

Biotechnology Published Insights

Coherent Market Insights

COVID-19 Sample Collection Kits Market, by Product Type (Swabs [Nasal swab, Nasopharyngeal swab, and Oropharyngeal swab], Viral Transport Media, and Others), by Application (Diagnostic and Research), by End User (Hospital and Clinics, COVID-19 Testing Centers, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Published Date : Mar 2022

COVID-19 sample collection kits are used for diagnosis and detecting SARS-CoV2 virus infection. The collection kits include vital reagents provided for collecting samples and delivering them to the laboratory where the testing services will be performed on such sample... View more

Coherent Market Insights

IPV Vaccines Market, by Vaccine Brand (POLIOVAC (PFS/SD), SHANIPV, POLIORIX, IPOL/IMOVAX, And POLYMILEX), by Distribution Channel (Private and Public), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Published Date : Mar 2022

The IPV are very safe. At the site of injection pain or mild redness may occur. To preventfrom Poliomyelitis, which affects children under age of 5. This infection can turn into irreversible paralysis and can also cause death. There are two types of vaccines used: an ... View more

Coherent Market Insights

Blood Based Biomarker Market, By Type (Screening Biomarker, Diagnosis Biomarker, and Others), By Disease (Cancer, Neurological Disorders, and Others), By Application (Diagnostics, Drug Discovery, and Personalized Medicine), and By Region (North America, Latin America, Europe, Asia-Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published Date : Feb 2022

A biomarker (short for biological marker) is an objective measure that captures what is happening in a cell or an organism at a given moment. Biomarkers can serve as early warning systems for health. A blood-based biomarker (biological marker in the patient’s bl... View more

Coherent Market Insights

MR Vaccines Market, by Vaccine Brand (MR Vaccine and MRBEV (BE LTD.), by Distribution Channel (Private and Public), and by Region (Commonwealth of Independent States (CIS) Countries, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Published Date : Feb 2022

The measles and rubella (MR) vaccine, which protects against measles and rubella, is recommended by the Centers for Disease Control and Prevention (CDC). MR vaccine should be given to children in two doses, the first at 12 to 15 months of age and the second at 4 to 6 ... View more

Coherent Market Insights

U.K. Cell and Gene Therapy Research Challenges Market, by Therapy Type (Cell Therapy (Stem Cells, T Cells, Dendritic Cells, and NK Cells) and Gene Therapy (Germline Gene Therapy and Somatic Gene Therapy)), and by Indication (Dermatology, Musculoskeletal, Oncology, Immunology, Cardiology & Neurology, and Others) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Published Date : Jan 2022

Gene therapy can be described as the transfer of genetic material mostly in a vector or carrier while cell therapy includes the transfer of cells with the applicable function into the patient’s body. In the broader sense, gene therapy involves introduction, with... View more

Coherent Market Insights

Angioimmunoblastic T-Cell Lymphoma Market by Drug (Azacitidine, Brentuximab Vedotin, Tipifarnib, AUTO4, MLN8237, CD7-CART and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028

Published Date : Dec 2022

Lymphomas are a type of cancer that affects lymphocytes which are further divided into two categories based on the type of cell into T-lymphocytes and B-lymphocytes. Angioimmunoblastic T-cell lymphoma (AITL) is rare form of non-Hodgkin lymphoma which effects the T-lym... View more

Subscribe Newsletter

Kindly subscribe for our latest news & articles.